Tagged with tech

Belgium Nipro’s Serge Kemps explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish a footprint in interventional cardiology. Kemps also outlines some of the challenges of moving towards a truly value-based healthcare system…

Greece Country managers from three leading medtech multinationals give their take on the key access challenges facing medical device companies in Greece.   New Access Models “While some value-based procurement agreements have been struck in the private sector, we are struggling to gain acceptance for such agreements in the public sector.…

Switzerland Taken from the recently published Swiss Biotech Report 2023, these figures cover major public and private financing transactions in Swiss biotech in the past year; major financing categories; capital investments in Swiss biotech companies; revenues, R&D expenses, profit/loss and liquidity; as well as well as the total number of biotech…

USA While the COVID-19 pandemic was a global wake-up call for many, life sciences stakeholders argue that not enough is being done to address the rising threats of further health crises and equate health security with national security, a necessity that requires consistent public funding. In addition, as a recent panel…

Belgium Alexander Alonso, GM of medtech giant BD’s Benelux affiliate explains the impact of the COVID-19 pandemic on its operations, the company’s 2025 strategy, and some of the most significant recent developments in Belgian healthcare such as the creation of hospital networks.   We are optimising internal and external processes while…

UAE Marwa Soliman of blood gas testing pioneer Radiometer explains how the company’s operations have developed in the MEA region, growing awareness of the importance of point-of-care diagnostics post-COVID, and how she aims to make sure that patients’ lives come first in all of Radiometer’s work.   COVID made healthcare regulators…

Belgium PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last conversation in 2020, and his hopes for establishing new alliances with manufacturers and Big Pharma players moving forward.   Our…

Greece Greek medtech industry veteran Dimitris Nikas outlines what makes him optimistic about the future of Greek healthcare, highlights the areas for systemic improvement and how EU recovery funding could help, and explains Greece’s relevance to Medtronic as an increasingly open early launch market for some of its most innovative new…

LatAm A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences investment destination. LatAm has a robust heritage of scientific achievement – Bernardo Houssay (1947) and César Milstein (1984) of Argentina…

China The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from Roche and CytoNiche Biotechnology’s new R&D centre.   COVID global emergency over but risks remain, says China health official (Reuters)…

Hong Kong In 2022, the biotech sector felt the impact of the challenges facing global capital markets and Hong Kong was no exception. Last year, only eight biotech companies listed on the Stock Exchange of Hong Kong Limited (HKEX), raising an aggregate of USD 473 million. Nonetheless, Hong Kong continues to serve…

Global In 2023, we face a new digital relations landscape where a customer and a brand more and more rely on personal data exchange and unique communication channels. In this new reality, marketing means are shifting towards direct communication and personalization, and generic campaigns are making way for communications that target…